MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.virs.2025.06.008

Медицинская библиотека · Virologica Sinica · 2025

Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up.

Deng Wen, Hao Hongxiao, Zhang Ziyu, Li Xinxin, Cao Weihua, Zhang Yaqin, Wang Shiyu, Gao Zixuan, Yao Linmei, Wang Shuojie, Wei Xin, Yi Wei, Zhao Linqing, Xie Yao, Li Minghui

СтатьяПеревод в очереди

Аннотация

To investigate the risk and influencing factors of long-term liver adverse events in chronic hepatitis B patients achieving hepatitis B surface antigen (HBsAg) clearance after pegylated interferon α (Peg-IFN α) treatment, a retrospective analysis was conducted on 456 patients at Beijing Ditan Hospital from 2008 to 2023 who achieved HBsAg clearance and discontinued Peg-IFN α treatment. The baseline was defined as the time of HBsAg clearance and treatment cessation. The endpoint was the first occurrence of liver adverse events (hepatocellular carcinoma or ascites) or last follow-up. Subsequently, we evaluated the incidence and risk factors of liver adverse events, along with changes in liver fibrosis, cirrhosis, and liver function indicators. During a median follow-up of 70 months, the incidence of liver adverse events was 2.30%, hepatocellular carcinoma 1.76%, and ascites 0.55%. Older age and cirrhosis were significant risk factors (HR 1.075 and 41.393, both P ​< ​0.01). The APRI score significantly improved at follow-up compared to baseline (0.53 vs. 0.25, P ​< ​0.001), and cirrhosis prevalence decreased from 5.70% to 0.88% (P ​< ​0.001). In conclusion, patients who achieved HBsAg clearance and discontinued Peg-IFN α treatment have a low risk of liver adverse events, while advanced age and cirrhosis remain major risk factors.

Для цитирования: Deng Wen, Hao Hongxiao, Zhang Ziyu, Li Xinxin, Cao Weihua, Zhang Yaqin, Wang Shiyu, Gao Zixuan, Yao Linmei, Wang Shuojie, Wei Xin, Yi Wei, Zhao Linqing, Xie Yao, Li Minghui. Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up.. Virologica Sinica. 2025. DOI: 10.1016/j.virs.2025.06.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.